oral glp-1 agonists receptor are generating a great deal of excitement as a potential inflection point in diabetes and obesity care. Amid the enthusiasm, however, a quieter and clinically important issue is Oral Small-Molecule GLP-1 Receptor Agonists:

A generic drug, like the liraglutide generic approved Monday, is a copy of a brand-name drug developed and made by another company

Data availability The datasets generated and analysed during the current study are not publicly available due to ethical consideration, but are available from the corresponding author on reasonable request

When switching is not possible Patients with type 1 diabetes cannot switch from insulin to a GLP-1 medication

Such cells are essential to sensing nutrients within the intestine and enabling their absorption into the body

[DOI] [PMC free article] [PubMed] [Google Scholar] 92.Palmer S.C., Tendal B., Mustafa R.A., Vandvik P.O., Li S., Hao Q., Tunnicliffe D., Ruospo M., Natale P., Saglimbene V., et al

With weight loss, there is also loss of fat-free mass, which raises concern for the development of sarcopenia